Tanja Morath
Overview
Explore the profile of Tanja Morath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mayer K, Ndrepepa G, Schroeter M, Emmer C, Bernlochner I, Schupke S, et al.
Clin Res Cardiol
. 2023 Feb;
112(9):1231-1239.
PMID: 36786829
Objective: The aim of this study was to assess the association between high on-aspirin treatment platelet reactivity (HAPR) and the subsequent risk of restenosis after percutaneous coronary intervention (PCI) with...
2.
Mayer K, Gewalt S, Morath T, Emmer C, Hilz R, Linhardt M, et al.
J Invasive Cardiol
. 2021 Jun;
33(9):E709-E715.
PMID: 34170841
Objectives: To compare vascular closure devices (VCD) with manual compression (MC) in patients on chronic oral anticoagulation (OAC) who undergo diagnostic coronary angiography in terms of vascular access-site complications. Methods:...
3.
Gewalt S, Lahu S, Ndrepepa G, Pellegrini C, Bernlochner I, Neumann F, et al.
J Atheroscler Thromb
. 2021 Apr;
29(5):747-761.
PMID: 33867409
Aim: Sex-specific analyses of direct head-to-head comparisons between newer P2Y inhibitors are limited. This study was conducted to assess the efficacy and safety of ticagrelor versus prasugrel in women and...
4.
Gewalt S, Helde S, Ibrahim T, Mayer K, Schmidt R, Bott-Flugel L, et al.
Circ Cardiovasc Interv
. 2018 Oct;
11(8):e006074.
PMID: 30354782
Background: The value of vascular closure devices (VCD) in women undergoing transfemoral catheterization has not been sufficiently investigated. Methods And Results: This is a sex-specific analysis of 1395 women enrolled...
5.
Harada Y, Michel J, Lohaus R, Mayer K, Emmer R, Lahmann A, et al.
Thromb Haemost
. 2017 Aug;
117(10):1989-1999.
PMID: 28783201
The DAPT score is a recently-proposed decision tool for guiding optimal duration of dual antiplatelet therapy (DAPT). It showed modest accuracy in prior derivation and validation cohorts of patients with...
6.
Lohaus R, Michel J, Mayer K, Lahmann A, Byrne R, Wolk A, et al.
Sci Rep
. 2016 Sep;
6:33054.
PMID: 27624287
In patients presenting with acute coronary syndrome (ACS) the optimal duration of dual-antiplatelet therapy after drug-eluting stent (DES) implantation remains unclear. At 6 months after intervention, patients receiving clopidogrel were...
7.
Bernlochner I, Mayer K, Orban M, Morath T, Jaitner J, Rossner L, et al.
Platelets
. 2016 Jun;
27(8):796-804.
PMID: 27275651
Patients with high on-treatment platelet reactivity (HTPR) on clopidogrel are at high risk for adverse cardiovascular events after percutaneous coronary intervention (PCI). The aim of the ISAR-ADAPT-PF study was to...
8.
Bernlochner I, Goedel A, Plischke C, Schupke S, Haller B, Schulz C, et al.
Eur Heart J
. 2015 Jul;
36(45):3202-10.
PMID: 26216931
Aims: The influence of reticulated platelets (RPs) on platelet inhibition by ticagrelor when compared with prasugrel is unknown. We aimed to determine the influence of RPs on adenosine diphosphate- (ADP-)...
9.
Orban M, Mayer K, Morath T, Bernlochner I, Hadamitzky M, Braun S, et al.
Thromb Res
. 2015 May;
136(1):87-93.
PMID: 25976448
Introduction: Mild therapeutic hypothermia (TH) is standard of care after cardiac arrest of any cause. However, its impact on on-treatment platelet reactivity and clinical outcome in patients with acute myocardial...
10.
Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, et al.
J Am Coll Cardiol
. 2015 May;
65(19):2154.
PMID: 25975486
No abstract available.